Related Experiment Videos
Bisoprolol pilot studies in myocardial infarction
E D de Muinck1, K I Lie, H J von Mengden
1Academisch Ziekenhuis, Groningen, The Netherlands.
Journal of Cardiovascular Pharmacology
|January 1, 1990
Summary
Beta-blockade with bisoprolol after myocardial infarction (MI) is safe and effective. Early intravenous and oral bisoprolol administration in MI patients shows good tolerability and hemodynamic stability.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockade is crucial post-myocardial infarction (MI) for reducing infarct size, mortality, and reinfarction.
- Bisoprolol, a selective beta1-blocker, offers once-daily dosing but lacked prior MI safety data.
Purpose of the Study:
- To evaluate the safety and efficacy of bisoprolol in patients following myocardial infarction.
- To assess the hemodynamic effects of early intravenous (IV) and subsequent oral bisoprolol administration post-MI.
Main Methods:
- Two open, uncontrolled pilot studies were conducted.
- Study 1: Dose-finding of IV bisoprolol (up to 5 mg) followed by oral 10 mg daily in 37 patients with 3-day-old MI.
- Study 2: IV bisoprolol (titrated 2.5 mg steps) within 6 hours of MI onset, followed by oral 10 mg daily, assessing central hemodynamics.
Main Results:
- Intravenous and oral bisoprolol administration was well tolerated in MI patients.
- The chosen dosing regimen demonstrated hemodynamic safety in the studied population.
- Early administration of bisoprolol post-MI showed promising tolerability.
Conclusions:
- Bisoprolol is a safe and well-tolerated option for early treatment post-myocardial infarction.
- The evaluated dosing strategy for bisoprolol is hemodynamically safe.
- Further investigation into bisoprolol's efficacy in MI is warranted based on these pilot findings.